ESMO updates from Presidential Symposium- European Society for Medical Oncology (ESMO)

European Society for Medical Oncology (ESMO) shared on LinkedIn:

“Positive outcomes in advanced or metastatic urothelial carcinoma reported from EV-302/KEYNOTE-A39 and CheckMate 901 indicate immunotherapy and Antibody Drug Conjugates (ADCs) as an alternative to first-line chemotherapy for the first time.

Results presented at today’s Presidential Symposium at ESMO23 show that enfortumab, vedotin plus pembrolizumab and adding nivolumab to chemotherapy prolonged median Progression-free survival (PFS) and median overall survival (OS) compared with chemotherapy.

Andrea Apolo, Bethesda, USA, comments on these findings on the ESMO Daily Reporter.
Read the full article here.”

Source: European Society for Medical Oncology (ESMO)/LinkedIn